Mersey J H
Am J Med. 1986 May 23;80(5B):68-72. doi: 10.1016/0002-9343(86)90855-7.
Two hundred twenty-six patients with mild to moderate hypertension were treated with terazosin in an open, multicenter study to determine the drug's long-term efficacy and safety. All patients had previously received terazosin in a short-term study; 66 patients entered from later short-term studies and had experienced a 7 mm Hg decrease in supine diastolic blood pressure in response to terazosin. Terazosin was administered once or twice daily either alone or in combination with a diuretic and/or a beta blocker. Supine systolic and diastolic blood pressures were significantly decreased from baseline during time intervals ending at 90, 180, 360, and 720 days of long-term therapy. No clinically significant trends were observed in pulse rate, clinical laboratory test results, physical examinations, or electrocardiograms. Patients had a tendency toward a slight weight gain. The most common adverse experiences attributed to terazosin monotherapy were dizziness and asthenia (9.7 percent and 6.6 percent, respectively). Adverse experiences were usually of mild or moderate severity. Of the 226 patients who underwent long-term therapy, 29 (13 percent) withdrew because of adverse experiences, and three (1 percent) withdrew because of uncontrolled blood pressure. This study demonstrates that terazosin is effective and safe for long-term treatment of hypertension.
在一项开放性多中心研究中，对226例轻至中度高血压患者使用特拉唑嗪进行治疗，以确定该药的长期疗效和安全性。所有患者此前均在一项短期研究中接受过特拉唑嗪治疗；66例患者来自后来的短期研究，他们在使用特拉唑嗪后仰卧位舒张压下降了7毫米汞柱。特拉唑嗪每日给药一次或两次，可单独使用，也可与利尿剂和/或β受体阻滞剂联合使用。在长期治疗的90、180、360和720天结束时的各个时间段内，仰卧位收缩压和舒张压均较基线水平显著下降。在脉搏率、临床实验室检查结果、体格检查或心电图方面未观察到具有临床意义的趋势。患者有轻微体重增加的倾向。特拉唑嗪单药治疗最常见的不良反应是头晕和乏力（分别为9.7%和6.6%）。不良反应通常为轻度或中度。在接受长期治疗的226例患者中，29例（13%）因不良反应退出，3例（1%）因血压控制不佳退出。本研究表明，特拉唑嗪长期治疗高血压有效且安全。
